- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Gael Forterre MBA
Chief Commercial Officer
Gael is the Chief Commercial Officer of Volition joining the team in 2021.
Gael is the Chief Commercial Officer of Volition joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q™ platform.
Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Path Inc. He is currently a non-executive board member of Integrated Wellness Holdings.
Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master’s in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.
“I am delighted to work with such a passionate team to drive commercialization of the product pipeline.”
Gael Forterre MBA
Chief Commercial Officer